[1]
|
World Health Organization (2020) Novel Coronavirus-China. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
|
[2]
|
HealthMap (2020) Novel Coronavirus (COVID-19). https://www.healthmap.org/covid-19/
|
[3]
|
Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z.F., Guo, Q.H., et al. (2020) Prevalence of Comorbidities and Its Effects in Patients Infected with SARS-CoV-2: A Systematic Review and Meta-Analysis. International Journal of Infectious Diseases, 94, 91-95. https://doi.org/10.1016/j.ijid.2020.03.017
|
[4]
|
Li, F. (2016) Structure, Function, and Evolution of Coronavirus Spike Proteins. Annual Review of Virology, 3, 237-261. https://doi.org/10.1146/annurev-virology-110615-042301
|
[5]
|
Sah, R., Rodriguez-Morales, A.J., Jha, R., Daniel, K., Chu, W., et al. (2020) Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal. Microbiology Resource Announcements, 9, e00169-20. https://doi.org/10.1128/MRA.00169-20
|
[6]
|
Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.L., Abiona, O., et al. (2020) Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science, 367, 1260-1263. https://doi.org/10.1126/science.abb2507
|
[7]
|
Zheng, J. (2020) SARS-CoV-2: An Emerging Coronavirus that Causes a Global Threat. International Journal of Biological Sciences, 16, 1678-1685. https://doi.org/10.7150/ijbs.45053
|
[8]
|
Donoghue, M., Hsieh, F. and Baronas, E. (2000) A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9. Circulation Research, 87, E1-E9. https://doi.org/10.1161/01.RES.87.5.e1
|
[9]
|
Li, S.C., Wang, Z.J. and Yang, X.H., Hu, B., Huang, Y.L. and Fan, S.J. (2017) Association between Circulating Angiotensin-Converting Enzyme 2 and Cardiac Remodelling in Hypertensive Patients. Peptides, 90, 63-68. https://doi.org/10.1016/j.peptides.2017.02.007
|
[10]
|
Touyz, R.M., Li, H. and Delles, C. (2020) ACE2 the Janus-Faced Protein—From Cardiovascular Protection to Severe Acute Respiratory Syndrome-Coronavirus and COVID-19. Clinical Science, 134, 747-750. https://doi.org/10.1042/CS20200363
|
[11]
|
D’Amico, F., Baumgart, D.C., Danese, S. and Peyrin-Biroulet, L. (2020) Diarrhea during COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clinical Gastroenterology and Hepatology, 18, 1663-1672. https://doi.org/10.1016/j.cgh.2020.04.001
|
[12]
|
Li, S.R., Tang, Z.J., Li, Z.H. and Liu, X. (2020) Searching Therapeutic Strategy of New Coronavirus Pneumonia from Angiotensin-Converting Enzyme 2: The Target of COVID-19 and SARS-CoV. European Journal of Clinical Microbiology & Infectious Diseases, 39, 1021-1026. https://doi.org/10.1007/s10096-020-03883-y
|
[13]
|
Liu, W.Z. and Li, H.L. (2020) COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. ChemRxi, Preprint. https://doi.org/10.26434/chemrxiv.11938173.v9
|
[14]
|
Tang, N., Li, D. and Wang, X. (2020) Abnormal Coagulation Parameters Are Associated with Poor Prognosis in Patients with Novel Coronavirus Pneumonia. Journal of Thrombosis and Haemostasis, 18, 844-847. https://doi.org/10.1111/jth.14768
|
[15]
|
US Centres for Disease Control and Prevention (2020) National Diabetes Statistics Report. US Centres for Disease Control and Prevention, Atlanta. https://www.cdc.gov/diabetes/data/statistics-report/index.html
|
[16]
|
Al Dawish, M.A., Robert, A.A., Braham, R., Al Hayek, A.A., Al Saeed, A. and Ahmed, R.A. (2016) Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature. Current Diabetes Reviews, 12, 359-368. https://doi.org/10.2174/1573399811666150724095130
|
[17]
|
International Diabetes Federation (2019) IDF Diabetes Atlas. 9th Edition. www.diabetesatlas.org
|
[18]
|
Yang, J.K., Feng, Y., Yuan, M.Y., Yuan, S.Y., Fu, H.J., Wu, B.Y., Sun, G.Z., Yang, G.R., Zhang, X.L., Wang, L., Xu, X., Xu, X.P. and Chan, J.C.N. (2006) Plasma Glucose Levels and Diabetes Are Independent Predictors for Mortality and Morbidity in Patients with SARS. Diabetic Medicine, 23, 623-628. https://doi.org/10.1111/j.1464-5491.2006.01861.x
|
[19]
|
Schoen, K., Horvat, N., Guerreiro, N.F.C., de Castro, I. and de Giassi, K.S. (2019) Spectrum of Clinical and Radiographic Findings in Patients with Diagnosis of H1N1 and Correlation with Clinical Severity. BMC Infectious Diseases, 19, Article No. 964. https://doi.org/10.1186/s12879-019-4592-0
|
[20]
|
Pal, R. and Bhadada, S.K. (2020) COVID-19 and Diabetes Mellitus: An Unholy Interaction of Two Pandemics. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14, 513-517. https://doi.org/10.1016/j.dsx.2020.04.049
|
[21]
|
Dean, R.G. and Burrell, L.M. (2007) ACE2 and Diabetic Complications. Current Pharmaceutical Design, 13, 2730-2735. https://doi.org/10.2174/138161207781662876
|
[22]
|
Chowdhury, S. and Goswami, S. (2020) COVID-19 and Type 1 Diabetes: Dealing with the Difficult Duo. International Journal of Diabetes in Developing Countries, 40, 315-320. https://doi.org/10.1007/s13410-020-00846-z
|
[23]
|
Tikellis, C. and Thomas, M.C. (2012) Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. International Journal of Peptide, 2012, Article ID: 256294.
|
[24]
|
Hartmann-Boyce, J., Morris, E., Goyder, C., Kinton, J., Perring, J. and Nunan, D. (2020) Managing Diabetes during the COVID 19 Pandemic. https://www.cebm.net/covid-19/managing-diabetes-during-the-covid-19-pandemic/
|
[25]
|
McKee, D.L., Sternberg, A., Stange, U., Laufer, S. and Naujokat, C. (2020) Candidate Drugs against SARS-CoV-2 and COVID-19. Pharmacological Research, 157, Article ID: 104859. https://doi.org/10.1016/j.phrs.2020.104859
|
[26]
|
Sun, M.L., Yang, J.M., Sun, Y.P. and Su, G.H. (2020) Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia. Chinese Journal of Tuberculosis and Respiratory Diseases, 43, E014. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0014
|
[27]
|
Phadke, M. and Saunik, S. (2020) Use of Angiotensin Receptor Blockers Such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus Infections—Novel Mode of Treatment. BMJ, 368, m406.
|
[28]
|
Ghaffari, H., Tavakoli, A., Moradi, A., Tabarraei, A., Bokharaei-Salim, F., Zahmatkeshan, M., et al. (2019) Inhibition of H1N1 Influenza Virus Infection by Zinc Oxide Nanoparticles: Another Emerging Application of Nanomedicine. Journal of Biomedical Science, 26, Article No. 70.
|
[29]
|
Hemila, H. (1997) Vitamin C Intake and Susceptibility to Pneumonia. The Pediatric Infectious Disease Journal, 16, 836-837.
|
[30]
|
Hans, P., Vanthuyne, A., Dewandre, P.Y., Brichant, J.F. and Bonhomme, V. (2006) Blood Glucose Concentration Profile after 10 mg Dexamethasone in Non-Diabetic and Type 2 Diabetic Patients Undergoing Abdominal Surgery. British Journal of Anaesthesia, 97, 164-170.
|
[31]
|
Sharma, S., Ray, A. and Sadasivam, B. (2020) Metformin in COVID-19: A Possible Role beyond Diabetes. Diabetes Research and Clinical Practice, 164, Article ID: 108183.
|
[32]
|
Liu, J., Li, X., Lu, Q., Ren, D., Sun, X., Rousselle, T., et al. (2019) AMPK: A Balancer of the Renin-Angiotensin System. Bioscience Reports, 39, Article ID: BSR20181994.
|
[33]
|
Plattner, F. and Bibb, JA. (2012) Serine and Threonine Phosphorylation. In: Brady, S.T., Siegel, G.J., Wayne Albers, R. and Price, D.L., Eds., Basic Neurochemistry, 8th Edition, Academic Press, Cambridge, 467-492. https://doi.org/10.1016/B978-0-12-374947-5.00025-0
|
[34]
|
Firstpost (2020) Metformin, an Oral Anti-Diabetic Drug, May Reduce Mortality in Women Infected by COVID-19, Claims Study. https://www.firstpost.com/health/metformin-an-oral-anti-diabetic-drug-may-reduce-mortality- in-women-infected-by-covid-19-claims-study-8519791.html
|
[35]
|
Gupta, R., Ghosh, A., Singh, A.K. and Misra, A. (2020) Clinical Considerations for Patients with Diabetes in Times of COVID-19 Epidemic. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14, 211-212. https://doi.org/10.1016/j.dsx.2020.03.002
|
[36]
|
Williams, S.J., Goddard-Borger, E.D. (2020) α-Glucosidase Inhibitors as Host-Directed Antiviral Agents with Potential for the Treatment of COVID-19. Biochemical Society Transactions, 48, 1287-1295. https://doi.org/10.1042/BST20200505
|
[37]
|
Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D. and Ran, X. (2008) Effect of Intensive Insulin Therapy on β-Cell Function and Glycaemic Control in Patients with Newly Diagnosed Type 2 Diabetes: A Multicentre Randomised Parallel-Group Trial. The Lancet, 371, 1753-1760. https://doi.org/10.1016/S0140-6736(08)60762-X
|
[38]
|
Swinnen, S.G., Hoekstra, J.B. and De Vries, J.H. (2009) Insulin Therapy for Type 2 Diabetes. Diabetes Care, 32, S253-S259. https://doi.org/10.2337/dc09-S318
|
[39]
|
Jones, M.C. (2007) Therapies for Diabetes: Pramlintide and Exenatide. American Family Physician, 75, 1831-1835.
|
[40]
|
Bischoff, H. (1995) The Mechanism of Alpha-Glucosidase Inhibition in the Management of Diabetes. Clinical and Investigative Medicine, 18, 303-311.
|
[41]
|
Ahidjo, B.A., Loe, M.W.C., Ng, Y.L., Mok, C.K. and Chu, J.J.H. (2020) Current Perspective of Antiviral Strategies against COVID-19. ACS Infectious Diseases, 10, 1624-1634. https://doi.org/10.1021/acsinfecdis.0c00236
|
[42]
|
Zhao, X., Guo, F., Comunale, M.A., Mehta, A., Sehgal, M., Jain, P. and Guo, J.T. (2015) Inhibition of Endoplasmic Reticulum-Resident Glucosidases Impairs Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 Spike Protein-Mediated Entry by Altering the Glycan Processing of Angiotensin I-Converting Enzyme 2. Antimicrobial Agents and Chemotherapy, 59, 206-216. https://doi.org/10.1128/AAC.03999-14
|
[43]
|
Rena, G., Hardie, D.G. and Pearson, E.R. (2017) The Mechanisms of Action of Metformin. Diabetologia, 60, 1577-1585. https://doi.org/10.1007/s00125-017-4342-z
|
[44]
|
Kirpichnikov, D., McFarlane, S.I. and Sowers, J.R. (2002) Metformin: An Update. Annals of Internal Medicine, 137, 25-33. https://doi.org/10.7326/0003-4819-137-1-200207020-00009
|
[45]
|
Nasri, H. and Rafieian-Kopaei, M. (2014) Metformin: Current Knowledge. Journal of Research in Medical Sciences, 19, 658-664.
|
[46]
|
Clements, A., Gao, B., Yeap, S.H.O., Wong, M.K.Y., Ali, S.S. and Gurney, H. (2011) Metformin in Prostate Cancer: Two for the Price of One. Annals of Oncology, 22, 2556-2560. https://doi.org/10.1093/annonc/mdr037
|
[47]
|
Kindrachuk, J., Ork, B., Hart, B.J., Mazur, S., Holbrook, M.R., Frieman, M.B. and Olinger, G.G. (2015) Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis. Antimicrobial Agents and Chemotherapy, 59, 1088-1099. https://doi.org/10.1128/AAC.03659-14
|
[48]
|
Lamos, E.M., Levitt, D.L. and Munir, K.M. (2016) A Review of Dopamine Agonist Therapy in Type 2 Diabetes and Effects on Cardio-Metabolic Parameters. Primary Care Diabetes, 10, 60-65. https://doi.org/10.1016/j.pcd.2015.10.008
|
[49]
|
Thornberry, N.A. and Gallwitz, B. (2009) Mechanism of Action of Inhibitors of Dipeptidyl-Peptidase-4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism, 23, 479-486. https://doi.org/10.1016/j.beem.2009.03.004
|
[50]
|
Pathak, R. and Bridgeman, M.B. (2010) Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors in the Management of Diabetes. Pharmacy and Therapeutics, 35, 509-513.
|
[51]
|
Abouelkheir, M. and El-Metwally, T.H. (2019) Dipeptidyl Peptidase-4 Inhibitors Can Inhibit Angiotensin Converting Enzyme. European Journal of Pharmacology, 862, Article ID: 172638. https://doi.org/10.1016/j.ejphar.2019.172638
|
[52]
|
Solerte, S.B., Di Sabatino, A., Galli, M. and Fiorina, P. (2020) Dipeptidyl Peptidase-4 (DPP4) Inhibition in COVID-19. Acta Diabetologica, 57, 779-783.
|
[53]
|
Meier, J.J. (2012) GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus. Nature Reviews Endocrinology, 8, 728-742.
|
[54]
|
Ceriello, A., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N.M., Rahelic, D. and Valensi, P. (2020) Issues of Cardiovascular Risk Management in People with Diabetes in the COVID-19 Era. Diabetes Care, 43, 1427-1432. https://doi.org/10.2337/dc20-0941
|
[55]
|
Guardado-Mendoza, R., Prioletta, A., Jiménez-Ceja, L.M., Sosale, A. and Folli, F. (2013) The Role of Nateglinide and Repaglinide, Derivatives of Meglitinide, in the Treatment of Type 2 Diabetes Mellitus. Archives of Medical Science, 9, 936-943. https://doi.org/10.5114/aoms.2013.34991
|
[56]
|
Kalra, S. (2014) Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Therapy, 5, 355-366. https://doi.org/10.1007/s13300-014-0089-4
|
[57]
|
Soni, S. and Dyck, J.R. (2020) The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients. Canadian Journal of Cardiology, 36, 1691.e3. https://doi.org/10.1016/j.cjca.2020.07.230
|
[58]
|
Rendell, M. (2004) The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus. Drugs, 64, 1339-1358. https://doi.org/10.2165/00003495-200464120-00006
|
[59]
|
Kahn, C.R., Chen, L. and Cohen, S.E. (2000) Unravelling the Mechanism of Action of Thiazolidinediones. The Journal of Clinical Investigation, 106, 1305-1307. https://doi.org/10.2165/00003495-200464120-00006
|
[60]
|
Carboni, E., Carta, A.R. and Carboni, E. (2020) Can Pioglitazone Be Potentially Useful Therapeutically in Treating Patients with Covid-19? Medical Hypotheses, 140, Article ID: 109776. https://doi.org/10.1016/j.mehy.2020.109776
|
[61]
|
Zhang, W., Xu, Y.Z., Liu, B., Wu, R., Yang, Y.Y., Xiao, X.Q. and Zhang, X. (2014) Pioglitazone Upregulates Angiotensin Converting Enzyme 2 Expression in Insulin-Sensitive Tissues in Rats with High-Fat Diet-Induced Nonalcoholic Steatohepatitis. The Scientific World Journal, 2014, Article ID: 603409. https://doi.org/10.1155/2014/603409
|